<DOC>
	<DOC>NCT02509585</DOC>
	<brief_summary>Prospective, open-label, within-patient, multi-center study of Lymphoseek in the detection of lymph nodes in subjects with known cancer of the cervix. All subjects will receive a single dose of 50 µg Lymphoseek radiolabeled with 2 mCi (74 MBq) Tc 99m.</brief_summary>
	<brief_title>A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Dextrans</mesh_term>
	<mesh_term>Technetium Tc 99m Pentetate</mesh_term>
	<criteria>Subject has provided written informed consent with HIPAA authorization Has cervical cancer and is a candidate for surgical intervention, with lymph node dissection being a part of the surgical plan. Is at least 18 years of age at the time of consent Has an ECOG performance status of Grade 0 to 2 Has the following International Federation of Gynecology and Obstetrics (FIGO) IA2IIA1staging. Subjects with a single enlarged/suspicious node on PET/CT will still be considered eligible as consistent with FIGO guidelines. If of childbearing potential, the subject has a negative pregnancy test within 48 hours before administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year The subject has had preoperative chemotherapy, immunotherapy, or radiation therapy within the 30 days prior to Lymphoseek administration Has had previous surgery or radiation to node basins that would be involved in the ILM procedure Has a known allergy to dextran Is breastfeeding or pregnant Has received any contrast material (Xray, MRI) or radiopharmaceutical within 48 hours prior to, or a therapeutic radiopharmaceutical (e.g., 131I) within 10 days before, or any radiopharmaceutical administration within 10 radioactive halflives before the administration of Lymphoseek or for whom administration of such substances is planned within 7 days after Lymphoseek administration Is scheduled for surgery and/or another invasive procedure other than the primary surgical intervention within the 3 days after Lymphoseek administration Has received an investigational product within the 30 days prior to Lymphoseek administration</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>